Related Experiment Video

Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Complement-targeted therapeutics: Are we there yet, or just getting started?

Daniel Ricklin1

  • 1Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

European Journal of Immunology
|September 12, 2024
PubMed

Insights

Complement system therapies have advanced significantly, offering viable treatments for numerous disorders. This review highlights key milestones and future directions in complement-targeted drug development.

Area of Science:

  • Immunology
  • Pharmacology
  • Drug Discovery

Background:

  • The complement system is a crucial immune mediator implicated in various diseases.
  • Targeting the complement system for therapeutic purposes was historically challenging.
  • Recent advancements have demonstrated the clinical and commercial feasibility of complement-targeted therapies.

Purpose of the Study:

  • To review the historical milestones in complement drug discovery and development.
  • To survey currently approved complement-specific therapeutics and their indications.
  • To provide insights into future advancements in the field.

Main Methods:

  • Literature review of complement drug discovery and development.
  • Analysis of approved complement-specific therapeutics and clinical indications.
  • Exploration of emerging trends and future prospects in complement therapy.

Main Results:

  • The field of complement-targeted therapy has expanded rapidly over the past two decades.
  • A dozen distinct complement-specific therapeutics are now available, treating eight disorders.
  • Numerous clinical trials and off-label uses further demonstrate the growing impact of these therapies.

Conclusions:

  • Complement-targeted therapies have evolved from challenging concepts to mainstream clinical options.
  • The field continues to advance, with ongoing research and development promising further breakthroughs.
  • Future advancements are expected to expand treatment modalities and address a broader range of conditions.
Keywords:
Complement systemDrug Discovery and DevelopmentTherapeutics

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.1K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
859